Library

Place of publication:
Medical alphabet, 2023, No. 21

Summary:
Purpose of the study. To study the effect of Mexidol ^® and Mexidol ^® Fort 250 on cognitive status of patients with post -shoe syndrome. Material and methods. 112 patients aged 24–60 years (55 men and 57 women) were examined, which were divided into two groups: the main one - 76 people with a confirmed coronaviral infection with symptoms that served as the basis for the diagnosis of post -icing syndrome (PKS), and control control - 36 people who have not painted coronavirus infection. Patients underwent a neurological and general somatic examination. For the study of cognitive functions, a brief scale for assessing the mental status (Mini Mental State Examination, MMSE) and a battery of tests for evaluating frontal dysfunction (Frontal Assessment Battle) was used. Memory was evaluated by the results of the subtest “memory” of khops, tests “10 words” and visual memory. The level of attention was investigated by the Schulta test and in the test “Verbal associations”, visual-spatial functions were evaluated using the clock test test. To correct the identified disorders, Mexidol ^® according to the scheme 500 mg times a day daily intravenously for 14 days with the subsequent transition to Mexidol Fort ^® 250 to 750 mg per day (one tablet 250 mg three times a day) for 2 months. Results. Patients with post -shoe syndrome were characterized by cognitive heterogeneity: in the structure of cognitive disorders they had lungs (46.0 %) and moderate (36.8 %) cognitive disorders. The course of treatment with Mexidol led to a decrease in the severity of the cognitive symptoms of the PKS. High efficiency and safety of prolonged sequential therapy with Mexidol (injections, then the tablet form Mexidol ^® Forte 250). Keywords: post-shoe syndrome, coronavirus infection SARS-COV-2 New, Cognitive Disorders, Mexidol ^® .

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2023, T. 123, No. 5

Summary:
Purpose of the study. To evaluate the effectiveness of consistent therapy with Mexidol and Mexidol Fort 250 in the correction of post -shoe syndrome (PKS) in patients with chronic cerebrovascular diseases (HCVZ). Material and methods. An analysis of the results of the examination and treatment of 110 patients with the CCVZ who suffered Covid-19 was carried out. Patients of the main group (OG, N = 55) received Mexidol (5 ml of iv in a drip for 14 days with the subsequent transition to the tablet form of Mexidol Fort 250, 1 tablet 3 times a day for 2 months); 55 patients of the comparison group (GS) did not receive antioxidants. All included in the study of patients conducted an MRI examination and detailed neuropsychological testing. Results. Patients have a significant improvement in the state of cognitive functions, the regression of asthenia symptoms, and the improvement of night sleep. Differences were statistically significant in comparison with both the initial level and with the GS. Conclusion. The appointment of the drug does not require age -related dose correction and goes well with basic therapy. The recommended scheme for the use of Mexidol: 14 days for 5 ml of iv or/m, then taking the drug Mexol Forter 250 in a dose of 1 tablet 3 times a day for 2 months. Key words: chronic cerebrovascular diseases, post -shoe syndrome, Mexidol, treatment.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2023, T. 123, No. 4

Summary:
Purpose of the study. To study the clinical and psychological profile and the quality of life of patients with post-shoe syndrome (PKS). Material and methods. 162 patients aged 24-60 years with a confirmed coronary reerovirus infection caused by the SARS-COV-2 virus, having symptoms that were the basis for the diagnosis of PKS, were examined. Patients underwent a neurological and general somatic examination with the identification of the corresponding neurological syndromes. They evaluated the intensity and nature of the pain (Mc Gill questionnaire), the level of psychosocial stress (Holmes-Road questionnaire), the severity of asthenia (the MFI-20 scale), the level of anxiety (Spielberger-Khanin questionnaire), depression (Bek scale). The quality of life was carried out by applying the Russian version of the SF-36 questionnaire. To correct the identified disorders, Mexidol was used 500 mg once a day every day in/in drip for 14 days, followed by the Mexidol Fort 250, 1 tablet 3 times a day for 2 months. Results . The course of treatment with Mexidol of patients with a PKS led to a decrease in the severity of subjective and objective symptoms of the PKS, asthenic, anxious and depressed disorders, and improved the quality of life of patients. Conclusion. The high efficiency and safety of consistent therapy with Mexidol (V/V, then orally Mexidol Forte 250) in patients with PKS are shown. Key words: post-shoe syndrome, coronavirus infection SARS-COV-2, emotional disorders, anxiety, depression, quality of life, Mexidol.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2023, T. 123, No. 3, Issue. 2

Summary:
Covid-19 development is associated with damage to various organs and systems of the body, including the development of acute ischemic stroke (AI). The article discusses modern ideas about the pathogenesis of AI at the Covid-19. The data on the choice of optimal therapy of patients with COVID-19 and acute AI, as well as the possibility of increasing the efficiency of rehabilitation measures, are analyzed. Information about the effectiveness of the use of the drug Mexidol in patients with COVID-19 and AI is given. Key words: ischemic stroke, Covid-19, treatment, rehabilitation, Mexidol.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2022, T. 122, No. 3

Summary:
the problem of post -shoe syndrome (PKS) attracts great interest due to the widespread prevalence and diversity of clinical manifestations. The main neurological manifestations of the PKS are considered. Information is given about the alleged mechanisms of the formation of PKS. The possibility of using the drug Mexidol for the treatment of patients with PKS is discussed. Key words: Covid -19, post -shoe syndrome, cognitive disorders, chronic brain ischemia, Mexidol, treatment.

Place of publication:
New therapeutic magazine "Non Nocera", November 2021

Summary:
A study of the effectiveness of the use of Mexidol in patients with COVID-19 amid chronic brain ischemia was carried out in St. Petersburg based on St. Petersburg GBUZ “City Hospital No. 38 named after N. A. Semashko. " 304 patients with HIGM and Covid-19 were observed; The 1st group (n = 152) was compiled by patients who received basic therapy and Mexidol, the 2nd group (n = 152) - received only basic therapy. For 14 days, Mexidol was prescribed intravenously with a drop of 500 mg (10 ml) per 400 ml of physiological solution, then Mexol Forte 250 was prescribed 1 tablet (250 mg) 3 times a day for 2 months. They evaluated the state of cognitive functions (Mosa scale), sleep (Spiegel questionnaire), asthenia (MFI-20 scale), quality of life (SIP questionnaire). The examination was carried out before the start of treatment, 30 and 75 days after its beginning. According to the results of the study, in patients in the administration of the drug Mexidol, there were more complete and early restoration of the state of cognitive functions (increase in indicators on the Mosa scale), regression of asthenia, and normalization of sleep. Among the patients of this group, by the end of the study, there were significantly more patients with complete or significant restoration of all indicators of the quality of life.

Place of publication:
New therapeutic journal Non Nocera, June/July 2021

Summary:
neurological complications of the coronavirus infection Covid-19 caused by the SARS-COV-2 virus are extremely diverse and are found in more than 30% of patients. So, with COVID -19, ischemic and hemorrhagic strokes, encephalopathy, meningitis, autoimmune diseases, for example, Guinen - Barre, violations of smell and taste, can develop. However, the fight against the Sarscov -2 virus does not end with screening and treatment of acute conditions. The delayed consequences for the health of people who have experienced Covid -19 are currently being actively studied.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2021, T. 121, No. 3, Issue. 2

Summary:
Purpose of the study. Studying the possibility of increasing the effectiveness of treatment of patients with chronic brain ischemia (HIGM) against the background of COVID-19 using the drug Mexidol. Material and methods. 304 patients with HIGM and Covid-19 were observed; The 1st group (n = 152) was compiled by patients who received basic therapy and Mexidol, the 2nd group (n = 152)-received only basic therapy. For 14 days, Mexidol was prescribed intravenously with a drop of 500 mg (10 ml) per 400 ml of physiological solution, then Mexol Forte 250 was prescribed 250 mg 3 times a day for 2 months. They evaluated the state of cognitive functions (Mosa scale), sleep (Spiegel questionnaire), asthenia (MFI-20 scale), quality of life (SIP questionnaire). The examination was carried out before the start of treatment, 30 and 75 days after its beginning. Results. Patients of the 1st group took place: a more complete and early restoration of the state of cognitive functions (an increase in indicators on the Mosa scale, p <0.01), astress regression (p <0.05), normalization of sleep (p <0.01) . Among patients of the 1st group, the end of the study turned out to be reliably more patients with complete or significant restoration of all indicators of the quality of life. Conclusion. Long-term sequential therapy with Mexidol with the drug provides a more complete restoration of impaired functions in patients with HIGM and Covid-19. Key words: Covid-19, SARS-COV-2 virus, chronic brain ischemia, asthenia, cognitive disorders, dementia, quality of life, Mexidol.

Place of publication:
Infectious diseases, 2021, T. 19, No. 1, P. 159–164

Summary:
the new coronavirus infection Covid-19 is characterized by high mortality and the absence of effective etiotropic therapy. Activation of oxidative stress may be one of the links in the pathogenesis of organ damage against the background of this infection. Target. Assessment of the ability of the drug Mexidol ^® to influence the speed of clinical improvement in pneumonia in hospitalized patients with a new Covid-19 coronaviral infection. The study includes 62 patients over the age of 18 years with a confirmed new coronavirus infection COVID-19 according to computed tomography (CT) of the lungs (stages KT1, KT2, KT3) and studies by the polymerase chain reaction from the nasopharynx and oropharynx on the SARS virus RNA SARS COV-2. After randomization, patients of the 1st group received infusion of Mexidol at a dose of 1000 mg/day for 7 days, patients of the 2nd group-infusion of isotonic sodium chloride solution. Compared to the control group in patients who received therapy with Mexidol, a reliably more pronounced decrease in body temperature, and a tendency to reduce the severity of shortness of breath were noted. In the Mexidol group, the concentration of superoxidsmutase has not changed, while in the control group there was a tendency to reduce it, the C-reactive protein decreased 2.2 times more than in the control group (p = 0.09). The tendency to a more rapid decrease in ferritin in the active intervention group has been identified. Mexidol therapy can have a positive effect on the clinical manifestations and the severity of laboratory-inflammatory syndrome in patients with a new Covid-19 coronaviral infection. Key words: new coronavirus infection Covid-19, oxidative stress, Mexidol.

Place of publication:
therapy No. 5 (39) 2020

Summary:
in the presented review, the pathogenesis of the coronavirus disease 2019 (Covid-19), features of the SARS-COV-2 virus are considered in detail. Given the great importance in the development of this infection of oxidative stress and hypoxia, it is advisable to use antioxidants and antihypoxants in the complex treatment of Covid-19, which may be useful and significantly improve the course of the disease. Key words : Covid-19, coronaviruses, oxidative stress, hypoxia.

Place of publication:
Infectious diseases, 2020, T. 18, No. 2, P. 97–102

Summary:
The article presents a review of the data that with a disease caused by COVID-19, along with impaired respiratory functions of the lungs (bronchoalveolar epithelium does not withheld oxygen, etc.), the level of hemoglobin and its ability to transfer oxygen to organs and tissues of the body, it decreases, the level of hema rises; Anokemia, oxygen starvation of organs and tissues of the whole organism and oxidative stress develops. Mexol, which was created in Russia, is widely used in medical practice, including diseases accompanied by ischemia and hypoxia. Mexol has an antihypoxic, antioxidant effect, the ability to restore mitochondrial respiratory dysfunction and, thus, affects key, basic processes in the cellular structures of the body and tissues of the body that occur in various hypoxic conditions. Mexidol can be useful in the complex therapy of patients with COVID-19. Key words: Covid-19, antioxidant, antihypoxant, hemoglobin, hypoxia, oxygen starvation, mexidol, mitochondrial dysfunction, oxidative stress.